TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 171 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.73 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $87,000 | -25.6% | 9,686 | +26.5% | 0.00% | – |
| Q2 2023 | $117,000 | -12.0% | 7,655 | +29.2% | 0.00% | – |
| Q1 2023 | $133,000 | -50.4% | 5,923 | -53.5% | 0.00% | – |
| Q4 2022 | $268,000 | +235.0% | 12,740 | +292.1% | 0.00% | – |
| Q3 2022 | $80,000 | -45.6% | 3,249 | -46.4% | 0.00% | – |
| Q2 2022 | $147,000 | -6.4% | 6,065 | -0.8% | 0.00% | – |
| Q1 2022 | $157,000 | -61.2% | 6,113 | -53.1% | 0.00% | – |
| Q4 2021 | $405,000 | +101.5% | 13,038 | +57.0% | 0.00% | – |
| Q3 2021 | $201,000 | +240.7% | 8,306 | +104.9% | 0.00% | – |
| Q2 2021 | $59,000 | +37.2% | 4,053 | +132.7% | 0.00% | – |
| Q1 2021 | $43,000 | +4200.0% | 1,742 | +3315.7% | 0.00% | – |
| Q4 2020 | $1,000 | – | 51 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |